1. FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies. (10th June 2014) Authors: Richard, F.A.; Scheinberg, M.A.; Thomas, M.; Chu, A.D.; Martin, R.S.; Hislop, C.; Petri, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0389 Effects of Chronic Treatment with Subcutaneous Blisibimod on Renal and Inflammation Biomarkers in Subjects with Systemic Lupus Erythematosus in Phase 2 PEARL-SC and Open-Label Extension Studies. (10th June 2014) Authors: Richard, F.A.; Scheinberg, M.A.; Thomas, M.; Chu, A.D.; Hislop, C.; Martin, R.S.; Petri, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗